Copaxone and Belsomra drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Copaxone (glatiramer acetate) and Belsomra (suvorexant). Common drug interactions include mobility decreased among females and decreased appetite among males.

The phase IV clinical study analyzes what interactions people have when they take Copaxone and Belsomra. It is created by eHealthMe based on reports of 36 people who take the same drugs from the FDA, and is updated regularly.

What is Copaxone?

Copaxone has active ingredients of glatiramer acetate. It is often used in multiple sclerosis. eHealthMe is studying from 56,931 Copaxone users. Check the latest studies of Copaxone.

What is Belsomra?

Belsomra has active ingredients of suvorexant. It is often used in insomnia. eHealthMe is studying from 12,961 Belsomra users. Check the latest studies of Belsomra.

On Jul, 20, 2026

36 people who take Copaxone and Belsomra together, and have interactions are studied.

Copaxone and Belsomra drug interactions.

What are the common drug interactions of Copaxone and Belsomra, by gender? *:

female:

Mobility decreased (ability to move is reduced)
Hepatic enzyme increased
Bedridden
Chest pain
Chills (felling of cold)
Dyspepsia (indigestion)
Erythema (redness of the skin)
Fall
Injection site erythema (redness at injection site)
Injection site mass

male:

Decreased appetite

What are the common drug interactions of Copaxone and Belsomra, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Confusional state
Lymphocyte count decreased
Psychiatric symptom
Rebound effect (take-back effect)
Visual acuity reduced (reduced clearness of vision)
Visual field defect
Visual impairment
White blood cell count decreased

50-59:

Mobility decreased (ability to move is reduced)
Hepatic enzyme increased
Infection
Bedridden
Chills (felling of cold)
Headache (pain in head)
Hepatic enzyme decreased
Liver disorder (liver diseases)
Nasopharyngitis (inflammation of the nasopharynx)
Hepatic steatosis (fatty liver disease)

60+:

Chest pain
Dyspepsia (indigestion)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Thyroid disorder (thyroid diseases)
Infection
Urticaria (rash of round, red welts on the skin that itch intensely)
Hypoaesthesia (reduced sense of touch or sensation)
Erythema (redness of the skin)
Fall
Fatigue (feeling of tiredness)

What are the existing conditions these people have? *

Gait Disturbance: 23 people, 63.89%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 12 people, 33.33%
Arthropathy: 4 people, 11.11%
Sinus Headache (headache caused by sinus infections): 3 people, 8.33%
Pain: 3 people, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Copaxone and Belsomra?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously